{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:45:19Z","timestamp":1792125919177,"version":"4.4.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 Ruth L. Kirschstein Institutional National Research Service Award"],"award-info":[{"award-number":["T32 Ruth L. Kirschstein Institutional National Research Service Award"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.016","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:10:37Z","timestamp":1790349037000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | The Evolving AML Treatment Paradigm"],"prefix":"10.1016","author":[{"given":"Elyse A.","family":"Olesinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-3107","authenticated-orcid":false,"given":"Brandon J.","family":"Aubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5848-6221","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2026.09.016_bib0001","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V13.12.1126.1126","article-title":"A comparative study of two regimens of combination chemotherapy in acute leukemia","volume":"13","author":"Frei","year":"1958","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V32.4.507.507","article-title":"Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults","volume":"32","author":"Ellison","year":"1968","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0003","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"issue":"6","key":"10.1016\/j.clml.2026.09.016_bib0004","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.V58.6.1203.1203","article-title":"Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B","volume":"58","author":"Rai","year":"1981","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","article-title":"Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study","volume":"60","author":"Yates","year":"1982","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2026.09.016_bib0006","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"Lowenberg","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0007","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0008","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.clml.2026.09.016_bib0009","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.clml.2026.09.016_bib0010","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"The Lancet Oncology"},{"issue":"5","key":"10.1016\/j.clml.2026.09.016_bib0011","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"10388","key":"10.1016\/j.clml.2026.09.016_bib0012","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0013","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/hematology.2025000755","article-title":"The promise of Menin inhibitors: from approval to triplet regimens","volume":"2025","author":"Thakur","year":"2025","journal-title":"Hematology"},{"issue":"17","key":"10.1016\/j.clml.2026.09.016_bib0014","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2024026700","article-title":"Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study","volume":"145","author":"Mantzaris","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.09.016_bib0015","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer discovery"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0016","first-page":"7","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood","volume":"133","author":"DiNardo","year":"2019","journal-title":"The Journal of the American Society of Hematology"},{"issue":"7","key":"10.1016\/j.clml.2026.09.016_bib0017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0018","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ajh.23661","article-title":"Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes","volume":"89","author":"Buckley","year":"2014","journal-title":"American Journal Of Hematology"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/leu.2013.176","article-title":"Declining rates of treatment-related mortality in patients with newly diagnosed AML given \u2018intense\u2019induction regimens: a report from SWOG and MD Anderson","volume":"28","author":"Othus","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2026.09.016_bib0020","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.269134","article-title":"Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?","volume":"106","author":"McCurdy","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.2022.280765","article-title":"Improved outcomes with \u201c7+3\u201d induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data","volume":"108","author":"Othus","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.clml.2026.09.016_bib0022","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl 3","key":"10.1016\/j.clml.2026.09.016_bib0023","first-page":"20","article-title":"Pharmacologically directed ara-C therapy for refractory leukemia","volume":"12","author":"Plunkett","year":"1985","journal-title":"Semin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2026.09.016_bib0024","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clml.2026.09.016_bib0025","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2026.09.016_bib0026","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.09.016_bib0027","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.clml.2026.09.016_bib0028","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1016\/j.clml.2026.09.016_bib0029","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"7728","key":"10.1016\/j.clml.2026.09.016_bib0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.clml.2026.09.016_bib0031","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0032","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.clml.2026.09.016_bib0033","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","article-title":"Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy","volume":"160","author":"Montero","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0034","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leukemia & lymphoma"},{"issue":"17","key":"10.1016\/j.clml.2026.09.016_bib0036","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.09.016_bib0037","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2026.09.016_bib0038","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0039","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase ib\/II study of Ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"18","key":"10.1016\/j.clml.2026.09.016_bib0040","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1002\/cam4.4182","article-title":"Improved survival with enasidenib versus standard of care in relapsed\/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis","volume":"10","author":"de Botton","year":"2021","journal-title":"Cancer Med"},{"issue":"23","key":"10.1016\/j.clml.2026.09.016_bib0041","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, Venetoclax, and Revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2026.09.016_bib0042","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood.2024027217","article-title":"Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.016_bib0043","series-title":"Results from Paradigm-a Phase 2 Randomized Multi-Center Study Comparing Azacitidine and Venetoclax to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia","author":"Fathi","year":"2025"},{"key":"10.1016\/j.clml.2026.09.016_bib0044","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.300374","article-title":"Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy","author":"Watts","year":"2026","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.clml.2026.09.016_bib0045","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.2023020102","article-title":"Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0046","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2025.08.016","article-title":"Comparative outcomes of intensive chemotherapy versus Venetoclax Plus hypomethylating agents in acute myeloid leukemia patients aged 60-75 years: a propensity score-adjusted cohort study","volume":"26","author":"Albliwi","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"10.1016\/j.clml.2026.09.016_bib0047","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/bloodadvances.2024012858","article-title":"Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML","volume":"8","author":"Bewersdorf","year":"2024","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2026.09.016_bib0048","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71037","article-title":"Better response and prognosis of venetoclax plus hypomethylating agents over intensive chemotherapy in young adults with newly diagnosed ASXL1-mutated acute myeloid leukemia","volume":"14","author":"Cai","year":"2025","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0049","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-024-01130-7","article-title":"Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: a propensity score-matched analysis based on International Consensus Classification","volume":"14","author":"Wan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41408-025-01363-0","article-title":"Genotype-guided comparison of VEN\/HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: a multicenter real-world study","volume":"15","author":"Chen","year":"2025","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.09.016_bib0051","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2024-202744","article-title":"Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics","volume":"144","author":"Aguirre","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.016_bib0052","article-title":"Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.09.016_bib0053","first-page":"1","article-title":"Comparative safety and effectiveness of Azacitidine plus venetoclax versus intensive chemotherapy in acute myeloid leukemia: a propensity score-matched analysis","author":"Chang","year":"2025","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0054","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","article-title":"Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.09.016_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70372","article-title":"Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: meta-analysis of a shifting treatment paradigm","volume":"132","author":"Perrone","year":"2026","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0056","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1186\/s12885-025-14311-9","article-title":"Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.clml.2026.09.016_bib0057","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood advances"},{"issue":"13","key":"10.1016\/j.clml.2026.09.016_bib0058","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2026.09.016_bib0059","series-title":"Post-Allogeneic Hematopoietic Cell Transplantation Outcomes Are Similar after Hypomethylating Agent\/Venetoclax and Intensive, Cytarabine-Based Remission Induction for Acute Myeloid Leukemia When Using Standardized, Contemporary Transplant Techniques","author":"Claiborne","year":"2025"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0060","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.009","article-title":"Febrile Neutropenia in acute leukemia. Epidemiology, etiology, pathophysiology and treatment","volume":"12","author":"Hansen","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2026.09.016_bib0061","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood-2019-123435","article-title":"Impact of primary antibacterial prophylaxis on neutropenic fever, infections, and antimicrobial resistance in newly diagnosed AML patients","volume":"134","author":"Caro","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0062","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.09.016_bib0063","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/bloodadvances.2020001728","article-title":"Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv"},{"issue":"32","key":"10.1016\/j.clml.2026.09.016_bib0064","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.2217\/fon-2022-0706","article-title":"Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy","volume":"18","author":"Huggar","year":"2022","journal-title":"Future Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.09.016_bib0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-1601","article-title":"Neutropenia, infections, and mortality across Acute Myeloid Leukemia induction strategies: a single center retrospective study","volume":"146","author":"Singh","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0066","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41375-025-02753-w","article-title":"Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis","volume":"40","author":"Geels","year":"2026","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.09.016_bib0067","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/j.clml.2019.03.007","article-title":"Anthracycline-induced cardiotoxicity in acute myeloid leukemia patients who undergo allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Pasvolsky","year":"2019","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"6_Part_2","key":"10.1016\/j.clml.2026.09.016_bib0068","article-title":"Cardiovascular events in patients with acute myeloid leukemia treated with venetoclax: a multicenter cohort study","volume":"5","author":"Filimon","year":"2026","journal-title":"JACC: Advances"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0069","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/phar.1733","article-title":"Azacitidine-induced pericarditis: a case series","volume":"36","author":"Newman","year":"2016","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"issue":"21","key":"10.1016\/j.clml.2026.09.016_bib0070","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1111\/febs.15583","article-title":"New insights into the activities and toxicities of the old anticancer drug doxorubicin","volume":"288","author":"van der Zanden","year":"2021","journal-title":"FEBS J"},{"key":"10.1016\/j.clml.2026.09.016_bib0071","unstructured":"Daunorubicin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed April 4, 2026. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548259\/."},{"key":"10.1016\/j.clml.2026.09.016_sbref0072","series-title":"StatPearls","article-title":"Daunorubicin","author":"Saleem","year":"2026"},{"key":"10.1016\/j.clml.2026.09.016_bib0073","unstructured":"Cytarabine. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed April 4, 2026. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548291\/."},{"key":"10.1016\/j.clml.2026.09.016_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.gore.2024.101383","article-title":"Maximizing ovarian function and fertility following chemotherapy in premenopausal patients: is there a role for ovarian suppression?","volume":"53","author":"Roof","year":"2024","journal-title":"Gynecologic Oncology Reports"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0075","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz008","article-title":"Cancer treatment-related infertility: a critical review of the evidence","volume":"3","author":"Poorvu","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0076","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117839","article-title":"Direct but no transgenerational effects of decitabine and vorinostat on male fertility","volume":"10","author":"Kl\u00e4ver","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clml.2026.09.016_bib0077","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/j.1939-4640.2003.tb03133.x","article-title":"5-Aza-2\u2032-deoxycytidine induces alterations in murine spermatogenesis and pregnancy outcome","volume":"24","author":"Kelly","year":"2003","journal-title":"Journal of Andrology"},{"issue":"23","key":"10.1016\/j.clml.2026.09.016_bib0078","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood.V126.23.4496.4496","article-title":"Symptom burden, quality of life, and distress in acute myeloid leukemia patients receiving induction chemotherapy: results of a prospective electronic patient-reported outcomes study","volume":"126","author":"LeBlanc","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0079","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.leukres.2014.11.028","article-title":"One day at a time: improving the patient experience during and after intensive chemotherapy for younger and older AML patients","volume":"39","author":"Ghodraty-Jabloo","year":"2015","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0080","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.clml.2026.09.016_bib0081","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2015.62.0468","article-title":"Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors","volume":"34","author":"Yabroff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0082","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamaoncol.2020.6343","article-title":"Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial","volume":"7","author":"El-Jawahri","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.016_bib0083","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11910-012-0264-9","article-title":"Chemotherapy-related cognitive dysfunction","volume":"12","author":"Wefel","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"10.1016\/j.clml.2026.09.016_bib0084","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/pon.1679","article-title":"Sexual functioning in long-term survivors of Hodgkin\u2019s lymphoma","volume":"19","author":"Recklitis","year":"2010","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/hematology.2020000087","article-title":"Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?","volume":"2020","author":"Chen","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.clml.2026.09.016_bib0086","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17474086.2023.2185603","article-title":"Assessing eligibility for treatment in acute myeloid leukemia in 2023","volume":"16","author":"Venditti","year":"2023","journal-title":"Expert Review of Hematology"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0087","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/asheducation-2014.1.8","article-title":"Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia","volume":"2014","author":"Klepin","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0088","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/asheducation-2016.1.339","article-title":"Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction","volume":"2016","author":"Rao","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2026.09.016_bib0089","unstructured":"Fred Hutch TRM calculator. Accessed April 11, 2026. https:\/\/trmcalculator.fredhutch.org\/."},{"issue":"1","key":"10.1016\/j.clml.2026.09.016_bib0090","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.97","article-title":"The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy","volume":"5","author":"Buckley","year":"2015","journal-title":"Blood Cancer Journal"},{"issue":"9","key":"10.1016\/j.clml.2026.09.016_bib0091","first-page":"571","article-title":"Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia","volume":"11","author":"Walter","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.016_bib0092","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2026.09.016_bib0093","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jgo.2020.10.004","article-title":"Validation of the \u201cfitness criteria\u201d for the treatment of older patients with acute myeloid leukemia: a multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)","volume":"12","author":"Borlenghi","year":"2021","journal-title":"Journal of Geriatric Oncology"},{"issue":"6","key":"10.1016\/j.clml.2026.09.016_bib0094","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.2023022611","article-title":"Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action","volume":"143","author":"Bhatt","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2026.09.016_bib0095","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2026.09.016_bib0096","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.09.016_bib0097","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.clml.2026.09.016_bib0098","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1200\/JCO-26-00347","article-title":"Risk prognostication after hypomethylating agents combined with Venetoclax in AML: the PRISM Risk model","volume":"44","author":"Lachowiez","year":"2026","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.016_bib0099","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2023011219","article-title":"A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML","volume":"8","author":"Ravindran","year":"2024","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.clml.2026.09.016_bib0100","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clml.2026.09.016_bib0101","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia\u2014from intensive chemotherapy combinations to chemotherapy-free regimens: a review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA oncology"},{"issue":"6","key":"10.1016\/j.clml.2026.09.016_bib0102","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood cancer journal"},{"key":"10.1016\/j.clml.2026.09.016_bib0103","article-title":"Phase I\/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML","volume":"9","author":"Yilmaz","year":"2025","journal-title":"Hemasphere"},{"issue":"22","key":"10.1016\/j.clml.2026.09.016_bib0104","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1200\/JCO-26-01159","article-title":"All-oral combination of revumenib, decitabine, and venetoclax for relapsed or refractory AML (SAVE)","volume":"44","author":"Issa","year":"2026","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.09.016_bib0105","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/ajh.70389","article-title":"Intensive induction in AML in the era of Venetoclax: a standing count for \u201c7+ 3\u201d?","volume":"101","author":"Tauro","year":"2026","journal-title":"American Journal of Hematology"},{"issue":"25","key":"10.1016\/j.clml.2026.09.016_bib0106","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.clml.2026.09.016_bib0107","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bjh.70253","article-title":"Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7+ 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia","volume":"208","author":"Lee","year":"2026","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.clml.2026.09.016_bib0108","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3+ 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"The Lancet Haematology"},{"issue":"33","key":"10.1016\/j.clml.2026.09.016_bib0109","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1016\/j.clml.2026.09.016_bib0110","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2510223","article-title":"All-oral treatment of newly diagnosed acute myeloid leukemia","volume":"394","author":"Roboz","year":"2026","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.clml.2026.09.016_bib0111","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00277-026-07076-z","article-title":"Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax\u2013a case series","volume":"105","author":"Lindemann","year":"2026","journal-title":"Annals of Hematology"},{"issue":"13","key":"10.1016\/j.clml.2026.09.016_bib0112","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Advances"},{"issue":"10","key":"10.1016\/j.clml.2026.09.016_bib0113","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","volume":"99","author":"Garciaz","year":"2024","journal-title":"American Journal of Hematology"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026039819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026039819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:56:34Z","timestamp":1792122994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026039819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":113,"alternative-id":["S2152265026039819"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | The Evolving AML Treatment Paradigm","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}